Contents
On this page
- The four classes and the structural determinants of function
- Definedness rather than size as the principal distinction
- Orthogonal characterisation and shared failure modes
- The regulatory framework and its implications for reporting
- Excipient considerations in biomacromolecule formulation
- Nucleic acids and the requirement for delivery vehicles
- The interface between biomacromolecules and nanomaterials
- Required content of the methods section
- Current gaps in knowledge
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Bio-macromolecules
Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation
Proteins, nucleic acids, polysaccharides and lipid assemblies constitute the four classes of bio-macromolecule, and the most informative distinction from small molecules is definedness rather than size. A small molecule has a single structure, whereas a biomacromolecule has a distribution of structures determined by its method of production. This property underlies the differences in their characterisation and regulation and in how methods sections describing them must be written.
The textbook definition of bio-macromolecules as four classes of large biological molecule built from repeating units is correct but of limited practical value. When reporting work on a protein, a nucleic acid, a polysaccharide or a lipid nanoparticle, the author is describing not a single compound but a population: a distribution of chain lengths, charge variants, glycoforms, aggregates and conformations whose profile depends on the production process. For this reason, a single assay cannot characterise a biologic, and the statement “the protein was purified and used” does not constitute an adequate methods section. This article examines the four classes and the principles of their characterisation and reporting.
Learning objectives
- The four classes, their building blocks, and the structural level that controls function in each
- Why “the process defines the product” is a structural statement about biomacromolecules rather than a regulatory principle alone
- Which characterisation techniques are orthogonal, and which only appear to corroborate one another
- How higher-order structure, heterogeneity and aggregation change what a specification can contain
- What a methods section must state about a biomacromolecule — source, construct, production system, purity by which measure, and storage history
- Where the evidence remains incomplete, particularly regarding the prediction of immunogenicity
Common misconceptions
- “A biomacromolecule is simply a large molecule.” Size is the least informative property. Definedness is the relevant property: a recombinant protein preparation is a population of related species, and the population constitutes the product.
- “Purity by SDS-PAGE or a single chromatogram establishes quality.” Electrophoretic purity provides no information on higher-order structure, aggregation state, glycosylation or activity. Techniques that are subject to the same failure modes do not corroborate one another.
- “Sequence determines function, so reporting the sequence is sufficient.” Sequence constrains function, whereas folding, post-translational modification and assembly state determine it. Two preparations with identical sequences can differ in potency and immunogenicity.
- “Biologics are specified in the same way as small molecules, with larger values.” They are specified on entirely different attributes: identity by orthogonal methods, charge and size heterogeneity, aggregation, host-cell impurities, and potency by a functional assay rather than an assay against a chemical reference standard.
- “Lipids are a minor class in this context.” In mRNA delivery, the lipid assembly is inseparable from activity, which makes lipids a central rather than a peripheral case.
The four classes and the structural determinants of function
Bio-macromolecules are large biological polymers and assemblies, conventionally grouped as proteins, nucleic acids, polysaccharides and lipids. The grouping remains useful, but it is most informative when each class is considered in terms of the structural level that controls its activity, because that level determines what must be measured.
For proteins, primary sequence constrains the possibilities and three-dimensional fold determines activity. Post-translational modification — glycosylation above all — modulates half-life, effector function and immunogenicity. The consequence is that a protein cannot be characterised by composition alone.
For nucleic acids, sequence carries the information and is in principle exactly verifiable, but delivery and stability largely determine whether any effect occurs. An mRNA with a correct sequence and no delivery vehicle is inert in vivo.
For polysaccharides, there is often no single correct structure to verify. Chain length distribution, branching pattern and degree of substitution are population properties, which is why polysaccharide materials are specified by distributions and functionality rather than by a structure. At this point the boundary with excipients also becomes indistinct: cellulose derivatives are polysaccharides and are specified in exactly this way.
For lipids, the individual molecule is comparatively small and the functional unit is the assembly — a bilayer, a micelle, a lipid nanoparticle. Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, describe mRNA delivery systems in which the ionisable lipid, helper lipid, cholesterol and PEG-lipid jointly determine whether the nucleic acid reaches the cytoplasm 5. The particle, not the lipid, is the entity to characterise.
The four classes, and the level at which each is controlled
| Class | Building block | Level that controls function | What must be reported |
|---|---|---|---|
| Proteins | Amino acids, peptide bonds | Three-dimensional fold, plus post-translational modification — glycosylation above all | Construct and sequence reference, expression system, fold or thermal stability measure, glycan profile where relevant, aggregation state, functional potency |
| Nucleic acids | Nucleotides, phosphodiester bonds | Sequence carries the information; delivery and intracellular stability decide whether it acts | Exact sequence and modifications, capping and tailing for mRNA, integrity measure, delivery vehicle composition, expression readout |
| Polysaccharides | Monosaccharides, glycosidic bonds | Population properties: chain-length distribution, branching, degree of substitution | Molecular weight distribution with method, degree of substitution, viscosity grade, source and lot |
| Lipids and lipid assemblies | Fatty acids, glycerol, sterols, head groups | The assembly — bilayer, micelle, lipid nanoparticle — not the individual molecule | Full lipid composition with molar ratios, particle size and polydispersity, zeta potential, encapsulation efficiency, dispersion medium |
Compiled from the sources cited on this page: Estapé Senti and colleagues in Advanced Drug Delivery Reviews on lipid nanoparticle composition; Jiskoot and colleagues and Hu and colleagues on protein higher-order structure and aggregation; Tang and colleagues in Progress in Polymer Science and Hasirci and colleagues on polymeric and nanoscale assemblies. The reporting column is a writing guide, not a compendial requirement list.
Definedness rather than size as the principal distinction
A small-molecule drug substance is a defined chemical entity: a structure, a salt form, a solid form, an impurity profile with named impurities at stated limits. A biomacromolecular drug substance is a population. Recombinant expression produces chains with heterogeneous N- and C-termini, variable glycan occupancy and structure, deamidation and oxidation that accumulate with handling, disulfide scrambling, and a proportion of dimer and higher aggregate. None of this constitutes contamination; it is the molecule as produced by that process in that system.
This is the basis of the familiar statement that the process defines the product. The statement is not a regulatory convenience but a description of how the distribution arises. A change in the cell line, the medium, the feed strategy, the purification or the final filtration changes the distribution. For this reason, comparability exercises between processes are a scientific requirement rather than an administrative one, and a methods section that omits the expression system has omitted part of the product description.
The consequence for reporting is that every quality statement requires a stated measure. “Purity greater than 95%” is uninformative in isolation, because purity by reducing SDS-PAGE, by size-exclusion chromatography and by charge-variant analysis are three different quantities that routinely disagree in the same preparation. Authors should state which measure was used, by which method, and preferably report more than one.
Orthogonal characterisation and shared failure modes
The governing principle is orthogonality: two methods corroborate each other only if their failure modes differ. Size-exclusion chromatography (SEC) and analytical ultracentrifugation (AUC) both report aggregation, but SEC can lose aggregates on the column and dissociate reversible species under dilution, which AUC does not; performing both is therefore informative. Performing SEC twice on different columns is not. Similarly, circular dichroism and differential scanning calorimetry both report conformational stability, but one reports secondary structure content and the other an unfolding transition, so a discrepancy between them is a finding rather than an error.
Three categories of attribute are routinely under-measured in submitted work. Higher-order structure is often omitted entirely, so that a correctly sized, correctly charged but inactive protein cannot be distinguished from an active one. Submicron and subvisible particles below the size range reported by SEC are frequently unmeasured, although they are central to the concern regarding aggregation and immunogenicity. Potency is often reported as a binding affinity when the relevant activity is functional; binding is necessary but not sufficient.
The high-concentration formulation literature illustrates the importance of these attributes most clearly. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, and Hu and colleagues, in the AAPS series, describe monoclonal antibody formulation above roughly one hundred milligrams per millilitre as dominated by protein–protein interaction, viscosity, opalescence and interfacial stress 14,17. These are all properties of the population and its environment, and they are not detected by an assay that measures the quantity of protein present.
Small molecule against biomacromolecule: what changes in characterisation
| Question | Small-molecule drug substance | Biomacromolecule |
|---|---|---|
| What is the identity? | A single structure, confirmed by NMR or MS against a reference standard | A population; identity established by orthogonal methods — peptide mapping, intact mass, charge-variant profile |
| What is the purity? | Chromatographic purity with named impurities at stated limits | Several different purities that disagree — by SDS-PAGE, by SEC, by charge variant; each must be named with its method |
| What are the impurities? | Synthetic by-products, degradants, residual solvents, elemental impurities | Product-related variants (aggregates, fragments, modified forms) plus process-related impurities (host-cell protein and DNA, leached ligand) |
| What is the relevant solid or physical state? | Polymorph, hydrate, particle-size distribution | Higher-order structure, aggregation state, subvisible and submicron particles, viscosity at use concentration |
| How is potency established? | Assay against a characterised chemical reference standard | A functional bioassay whose readout must be stated; binding affinity alone is not potency |
| What defines the product? | The specification | The specification and the process together — change the process and the distribution changes |
A reporting contrast assembled from the biologics formulation and characterisation literature cited on this page, read against the drug substance expectations described in ICH Q8(R2) and the pharmacopoeial small-molecule framework. Qualitative by design; no figures are implied.
The regulatory framework and its implications for reporting
Because the product is a distribution produced by a process, the regulatory apparatus for biologics attaches to the process as well as to the material: cell bank characterisation, viral safety, comparability after process change, and potency by functional assay. ICH Q8(R2) still supplies the general structure — a quality target product profile, critical quality attributes, and a design space linking material attributes and process parameters — but the attributes it is applied to are different from those in a small-molecule development programme 1.
For cell and gene therapies, this framework is further strained. The Committee for Advanced Therapies, writing in Nature Reviews Drug Discovery, set out why advanced therapy medicinal products fit a drug-substance-plus-drug-product model poorly: the material may be patient-specific, the potency assay may be the only meaningful identity test, and the manufacturing and the administration may not be separable 24. Kohn, Chen and Spencer, in Gene Therapy, review the successes and the remaining obstacles in clinical gene therapy in the same manner, with explicit acknowledgement of unresolved issues 8.
The implications for a manuscript are specific. Small-molecule specification language should not be adopted. Authors should report the construct, the production system, the purification, the attributes measured with their methods, the potency assay and what it measures, and the handling history of the material. Our API definition page sets out the small-molecule version of the same list, and the contrast between the two is instructive.
Excipient considerations in biomacromolecule formulation
Excipient selection for biologics addresses a different set of failure modes. Compaction, disintegration and dissolution are irrelevant; colloidal and conformational stability, interfacial protection and viscosity are the targets 14,17. The working set is buffers to hold pH where the molecule is most stable, sugars and polyols as stabilisers and tonicity agents, amino acids such as arginine and histidine for viscosity and aggregation control, non-ionic surfactants to protect air–liquid and solid–liquid interfaces, and chelators where metal-catalysed oxidation is a route.
The principal constraint in high-concentration work is clinical rather than chemical: subcutaneous self-administration in a small volume requires a high concentration, and the failure modes worsen non-linearly 14. Jiskoot and colleagues present this as an open problem, and that assessment should be reflected in how a formulation paper is written — as a partial solution within stated limits, not as a solved case. Our excipient page covers the small-molecule contrast, and applications of active pharmaceutical ingredients covers how route selection drives it.
Nucleic acids and the requirement for delivery vehicles
Nucleic acid therapeutics separate the two problems unusually clearly. The sequence is verifiable to a standard that no protein can match; the difficulty lies entirely in delivery, stability and expression. Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, review lipid nanoparticles and alternatives for mRNA in cancer immunotherapy, where the lipid composition determines endosomal escape and therefore whether any translation occurs 5.
For viral vectors, Shchaslyvyi and colleagues, in Pharmaceuticals, survey approved gene therapy products by vector type; Au, Isalan and Mielcarek, in Frontiers in Medicine, pool adeno-associated virus usage across clinical settings; Alhakamy and colleagues, in Drug Discovery Today, trace the preclinical-to-clinical path 6,10,15. The scale is substantial: Ginn and colleagues, in The Journal of Gene Medicine, count 3,900 gene therapy trials worldwide across 46 countries in their update to 2023 4. Kohn, Chen and Spencer, in Gene Therapy, give the balancing account of what has and has not worked.
For cell products the active principle is a cell population. Hu, Korsos and Palomba, in Frontiers in Oncology, review CAR T-cell therapy for aggressive B-cell lymphomas, and Lulla and colleagues cover non-Hodgkin lymphoma in Clinical Advances in Hematology and Oncology 3,19. In this context, “dose” is a cell number with a viability and phenotype specification, and release testing is biological. The biomacromolecule — the receptor construct — is one component of a product that consists mostly of cells.
The interface between biomacromolecules and nanomaterials
Biomacromolecular assemblies occupy the same size range as engineered nanomaterials, and the overlap extends beyond dimensions. Zheng and colleagues, in RSC Advances, note the European Commission definition of nanomaterials as those in which 50% or more of the particles have one or more external dimensions in the 1–100 nm range — the regime occupied by lipid nanoparticles, virus-like particles, protein cages and polysaccharide gels alike 12. Tang and colleagues, in Progress in Polymer Science, cover polymeric nanostructured materials used for the same biomedical purposes, and Hasirci and colleagues, in the Journal of Biomaterials Science, Polymer Edition, give the early systematic account of nanobiomaterials as a field 21,25.
The practical consequence is that when the biomacromolecule is an assembly rather than a single chain, nanomaterial characterisation expectations apply: hydrodynamic size with a polydispersity measure, zeta potential, morphology by electron microscopy, and the dispersion state in the biological medium actually used 25. Our page on nano-biomaterials sets those expectations out in full, and material selection for drug development covers how they feed a selection decision.
Required content of the methods section
The characteristic failure in biomacromolecule methods sections is the single-sentence description: the protein was expressed, purified and used. A reader requires six items of information. The construct, including tags, linkers and any mutations relative to a named reference sequence. The production system, including cell line or strain and the relevant expression conditions. The purification, in sufficient detail to make clear which species was selected. The purity, with the measure and method named — preferably two orthogonal measures. The activity, by a functional assay with its readout stated. The handling history: storage buffer, concentration, temperature, freeze–thaw cycles, and whether the material was filtered before use.
Handling history is the item most often missing and the one that most often explains a failed replication. Freeze–thaw cycling, agitation during transport and adsorption to container surfaces all generate aggregate without changing anything that an assay for protein content would detect. The comparison below sets the usual version against an adequate one.
A protein materials paragraph, two ways
Not usable by a reader
Recombinant human interleukin-based fusion protein was expressed in E. coli, purified by affinity chromatography and used for all experiments. Purity was greater than 95% as judged by SDS-PAGE. Protein concentration was determined by absorbance at 280 nm.
What exactly was expressed? No construct boundaries, linker, tag or mutations, so the protein cannot be reproduced.
Purity by which measure? SDS-PAGE purity provides no information on aggregation, which is the attribute most likely to affect the result.
Was the material folded and active? Nothing is reported on higher-order structure or function — an inactive preparation would be described identically.
Was endotoxin controlled? Unaddressed in an E. coli product used in cell-based work, where it is a recognised confounder.
How was it stored and handled? No buffer, concentration, freeze–thaw count or filtration, which is the most common unexplained cause of a failed replication.
Usable
The fusion construct comprised residues 24 to 177 of the human cytokine (UniProt reference given in the supplement) joined by a GGSGGS linker to a C-terminal human IgG1 Fc bearing the N297A substitution, with an N-terminal His-6 tag removed by TEV protease before use. The protein was expressed in E. coli BL21(DE3) at 18 degrees C for 16 h after induction, refolded by dropwise dilution, and purified by nickel affinity chromatography followed by preparative size-exclusion chromatography, from which only the monomer peak was collected. Purity was 97% by analytical SEC (monomer, by area) and 96% by reducing SDS-PAGE densitometry, with aggregate content below 1% by SEC and confirmed below 2% by sedimentation velocity analytical ultracentrifugation. Endotoxin was below 0.1 EU per mg by LAL assay. Secondary structure was consistent with the reference preparation by circular dichroism, and the thermal unfolding midpoint was 58.4 degrees C by differential scanning fluorimetry. The material was stored at 2 mg/mL in 20 mM histidine, 150 mM NaCl, 0.02% polysorbate 80, pH 6.0, at minus 80 degrees C in single-use aliquots; all experiments used material subjected to exactly one freeze-thaw cycle and filtered at 0.22 micrometres immediately before use. Potency was confirmed in each experimental batch by the reporter-gene assay described in section 2.6, with the EC50 falling within the stated range.
The construct is fully specified against a named reference, including linker, tag and mutation, so that another group can reproduce it.
Purity is given by two orthogonal methods, and aggregate content by two methods with different failure modes.
Structure and function are both evidenced, so an inactive preparation could not pass undetected.
A justified acceptance limit for endotoxin is established and stated, as applicable to the material and its intended use, removing a standard confounder in cell-based work.
Handling is specified down to freeze–thaw count and filtration, which makes the material state reproducible rather than assumed.
The second version is longer because a biomacromolecule requires more information than a small molecule to be identified at all — it is a population, not a structure. Every added item is something the authors have already measured or could measure once; none of it is a claim drawn from the literature.
Current gaps in knowledge
Immunogenicity prediction is the largest open gap. Aggregation is a recognised risk factor and is treated as such throughout the formulation literature, but none of the sources here establishes a quantitative relationship between a measurable aggregate level and a clinical immunogenicity rate 14,17. Aggregate burden should be reported by orthogonal methods and described as a risk factor; an aggregate figure should not be presented as a safety margin.
Second, the relationship between higher-order structural measurements and potency is qualitative. A loss of thermal stability or a change in secondary structure content signals a problem, but the magnitude of a conformational change cannot currently be translated into a predicted loss of activity, which is why the functional assay remains the arbiter.
Third, for nanoparticulate biomacromolecular assemblies, in vitro release and in vivo behaviour are not reliably related, and the measurement of release is itself method-dependent because separating released from encapsulated material is technically difficult. Such data should be presented as a comparability and control tool rather than as a predictor.
Finally, the field’s own balance of success and failure is openly contested in the primary literature: Kohn, Chen and Spencer in Gene Therapy and the Committee for Advanced Therapies in Nature Reviews Drug Discovery both treat durability, manufacturing reproducibility and long-term safety as unresolved 8,24. A manuscript that reflects this uncertainty appears better informed, not weaker. The concepts and definitions hub places these terms alongside the device-side equivalents in material selection for medical devices.
Key points
Key points
Bio-macromolecules fall into four classes, namely proteins, nucleic acids, polysaccharides and lipid assemblies, and the most informative distinction from small molecules is definedness rather than size. Each preparation is a population of related species whose distribution is determined by the production process; for this reason, the process forms part of the product definition and no single assay is sufficient for characterisation. Characterisation should be orthogonal, the measure underlying every purity figure should be named, higher-order structure and aggregation should be measured in addition to content, and potency should be established by a functional assay. Reports should specify the construct, the production system, the purification, two purity measures, the activity and the full handling history.
Application to your study
Application to your study
- The construct should be specified against a named reference sequence. The specification should include residue boundaries, linkers, tags and whether they were removed, and every substitution relative to the reference.
- The production system and relevant conditions should be named. Cell line or strain, induction or feed regime and temperature form part of the product description rather than background information.
- Every purity value should be accompanied by its method of measurement. A statement such as “97% monomer by analytical SEC” is preferable to “greater than 95% pure”. Two measures with different failure modes should be reported.
- Aggregation should be reported using orthogonal methods, including the submicron range. Size-exclusion chromatography (SEC) alone may lose or dissociate the species being quantified.
- Higher-order structure should be measured, in addition to size and charge. A thermal transition or a circular dichroism (CD) spectrum compared with a reference preparation distinguishes folded from unfolded material.
- Potency should be established with a functional assay, and its readout stated. Binding affinity is necessary but not sufficient.
- The handling history should be recorded in full. This includes buffer, concentration, storage temperature, number of freeze–thaw cycles, filtration and agitation during transport.
- Endotoxin limits should be established for any bacterially expressed material used in cell or animal studies. The method and the limit should be reported, rather than the absence of endotoxin assumed.
- For assemblies, nanomaterial characterisation should be added. This includes hydrodynamic size with polydispersity, zeta potential, morphology and dispersion state in the relevant biological medium.
- Aggregate burden should be described as a risk factor rather than as a safety margin. No source supports the conversion of an aggregate level into a predicted rate of immunogenicity.
Frequently asked questions
Proteins, nucleic acids, polysaccharides and lipids, the last usually encountered as assemblies rather than single molecules. The classification is by building block — amino acids, nucleotides, monosaccharides, fatty acids and related units — but the more useful question is which structural level controls function in each. For proteins it is the fold plus post-translational modification; for nucleic acids the sequence carries the information while delivery and stability decide whether it acts; for polysaccharides the controlling properties are population properties such as chain-length distribution and degree of substitution; for lipids it is the assembly, which is why in mRNA delivery the lipid nanoparticle rather than any one lipid is the entity to characterise.
Because a biologic drug substance is a distribution of related species rather than a single defined structure. Recombinant expression produces heterogeneous termini, variable glycosylation, deamidation and oxidation that accumulate with handling, and a proportion of aggregate. That distribution is determined by the process, so the process forms part of the product definition and a process change requires a comparability exercise. In practice, no single assay characterises the material: purity by SDS-PAGE, by size-exclusion chromatography and by charge-variant analysis are three different quantities that routinely disagree, and higher-order structure and aggregation state must be measured separately from content.
It is a structural statement, not a regulatory formality. The population of species in a biologic preparation — glycoform distribution, charge variants, aggregate fraction, modified residues — arises from the cell line, medium, feed strategy, purification and final processing. A change in any of these alters the distribution, even though the nominal sequence does not change. For this reason, comparability after a process change is a scientific requirement, and a methods section that omits the expression system has omitted part of the description of the material. For cell and gene therapies the Committee for Advanced Therapies, in Nature Reviews Drug Discovery, argue the framework strains further still.
Two methods are orthogonal when their failure modes differ, so that agreement between them is informative. Size-exclusion chromatography and sedimentation velocity analytical ultracentrifugation both report aggregation, but SEC can lose aggregates on the column and dissociate reversible species on dilution, which AUC does not — so performing both is worthwhile. Performing SEC on two different columns is not orthogonal. The same logic applies to identity (peptide mapping plus intact mass) and to stability (circular dichroism plus a thermal transition measurement). Where two orthogonal methods disagree, the disagreement is a finding that should be reported rather than a problem to be resolved without comment.
Yes, and it is the item most often missing. Freeze–thaw cycling, agitation during transport and adsorption to container surfaces all generate aggregate and can reduce activity without changing anything that a protein content assay would detect. A reader who cannot reconstruct the handling history of the material cannot diagnose a failed replication. Authors should state the storage buffer with its full composition and pH, the concentration, the storage temperature, whether aliquots were single use, the number of freeze–thaw cycles the experimental material underwent, and whether it was filtered immediately before use.
It is substantial and concentrated. Ginn and colleagues, in The Journal of Gene Medicine, count 3,900 gene therapy trials worldwide across 46 countries in their update to 2023. Shchaslyvyi and colleagues, in Pharmaceuticals, survey the approved products by vector type, and Au, Isalan and Mielcarek pool adeno-associated virus usage across clinical settings in Frontiers in Medicine. Kohn, Chen and Spencer, in Gene Therapy, provide the counterbalancing account: durability of effect, manufacturing reproducibility and long-term safety remain open questions, and a manuscript that acknowledges this appears better informed rather than less confident.
Not quantitatively, and authors should state this in the discussion rather than imply otherwise. Aggregation is a recognised immunogenicity risk factor and is treated as such throughout the protein formulation literature, including by Jiskoot and colleagues in the Journal of Pharmaceutical Sciences. However, none of the sources available here establishes a numerical relationship between a measured aggregate level and a clinical immunogenicity rate. The defensible position is to report aggregate burden by orthogonal methods across the size range, including submicron particles, and to describe it as a risk factor to be minimised — not as a demonstrated safety margin.
Neither label applies straightforwardly, and this is itself the informative answer. Estapé Senti and colleagues, in Advanced Drug Delivery Reviews, describe mRNA delivery systems in which the ionisable lipid, helper lipid, cholesterol and PEG-lipid jointly determine endosomal escape and therefore whether any protein is expressed. Formally the lipids are excipients; functionally the particle is the product, and a change in lipid composition changes the pharmacology. The practical consequence for reporting is that the particle should be characterised and reported as an entity — full lipid composition with molar ratios, size and polydispersity, zeta potential, encapsulation efficiency and dispersion medium — rather than as a list of lipids in a formulation table.
References
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
- Hu B, Korsos V, Palomba ML. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas. Frontiers in Oncology. 2024;14:1394057. doi:10.3389/fonc.2024.1394057 read 9 October 2026. doi.org/10.3389/fonc.2024.1394057
- Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
- Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
- Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
- Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
- Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Therapy. 2023;30(10-11):738-746. doi:10.1038/s41434-023-00390-5 read 9 October 2026. doi.org/10.1038/s41434-023-00390-5
- Liu R, Luo C, Pang Z, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chemical Letters. 2022. doi:10.1016/j.cclet.2022.05.032 read 9 October 2026. doi.org/10.1016/j.cclet.2022.05.032
- Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Frontiers in Medicine. 2022;8. doi:10.3389/fmed.2021.809118 read 9 October 2026. doi.org/10.3389/fmed.2021.809118
- Zheng X, Xie J, Zhang X, Sun W, Zhao H, Li Y, Wang C. An overview of polymeric nanomicelles in clinical trials and on the market. Chinese Chemical Letters. 2021;32(1):243-257. doi:10.1016/j.cclet.2020.11.029 read 9 October 2026. doi.org/10.1016/j.cclet.2020.11.029
- Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
- Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
- Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
- Alhakamy NA, Curiel DT, Berkland CJ. The era of gene therapy: From preclinical development to clinical application. Drug Discovery Today. 2021;26(7):1602-1619. doi:10.1016/j.drudis.2021.03.021 read 9 October 2026. doi.org/10.1016/j.drudis.2021.03.021
- Kumar SSD, Abrahamse H. Advancement of nanobiomaterials to deliver natural compounds for tissue engineering applications. International Journal of Molecular Sciences. 2020;21(18):1-27. doi:10.3390/ijms21186752 read 9 October 2026. doi.org/10.3390/ijms21186752
- Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
- Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
- Lulla PD, Hill LC, Ramos CA, Heslop H. The use of chimeric antigen receptor T cells in patients with non-hodgkin lymphoma. Clinical Advances in Hematology and Oncology. 2018;16(5):375-386. read 9 October 2026. scholars.houstonmethodist.org
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B, Chen X. Polymeric nanostructured materials for biomedical applications. Progress in Polymer Science. 2016;60:86-128. doi:10.1016/j.progpolymsci.2016.05.005 read 9 October 2026. doi.org/10.1016/j.progpolymsci.2016.05.005
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
- Committee for Advanced Therapies (CAT) and CAT Scientific Secretariat. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery. 2010;9(3):195-201. doi:10.1038/nrd3052 read 9 October 2026. doi.org/10.1038/nrd3052
- Hasirci V, Vrana E, Zorlutuna P, Ndreu A, Yilgor P, Basmanav FB, Aydin E. Nanobiomaterials: a review of the existing science and technology, and new approaches. Journal of Biomaterials Science, Polymer Edition. 2006;17(11):1241-1268. doi:10.1163/156856206778667442 read 9 October 2026. doi.org/10.1163/156856206778667442
- Lu J, Rohani S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Current Medicinal Chemistry. :884-905. doi:10.2174/092986709787549299 read 9 October 2026. doi.org/10.2174/092986709787549299
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation. Pubrica. https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/
Pubrica Academy. “Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/.
Pubrica Academy (2026) Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/ (Accessed: 15 October 2026).
Pubrica Academy. “Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/
Pubrica Academy, ‘Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/> accessed 15 October 2026.
Pubrica Academy. Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/
Pubrica Academy, “Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/
@misc{what_are_bio_macromolecules_2026,
author = {{Pubrica Academy}},
title = {Bio-Macromolecules: The Four Classes and the Principles of Their Characterisation},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/what-are-bio-macromolecules/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Biomacromolecule materials block for a methods section
This checklist should be completed before the paragraph is written. It covers the six items a reader requires — construct, production, purification, purity, activity, handling — together with the assembly section for materials that are particles rather than single chains. Incomplete lines correspond to the questions a reviewer is likely to ask.
BIOMACROMOLECULE MATERIALS BLOCK
Class: [ ] protein [ ] nucleic acid [ ] polysaccharide [ ] lipid assembly
1. CONSTRUCT / IDENTITY
Reference sequence or accession ..... ______________________________
Residue / nucleotide boundaries ..... ______________________________
Tags and linkers .................... ______________________________
Tag removed before use? [ ] yes, by ____________ [ ] no
Substitutions vs reference .......... ______________________________
For mRNA: cap ______ tail ______ modified bases ______________
For polysaccharide: source ____________ degree of substitution ______
2. PRODUCTION
System (cell line / strain / synthesis) ______________________________
Expression or synthesis conditions .. ______________________________
Lot or batch identifier ............. ______________________________
Single lot used throughout? ......... [ ] yes [ ] no (state where it changed)
3. PURIFICATION
Steps, in order ..................... ______________________________
Species selected for ................ ______________________________
(e.g. monomer peak only; which fraction and why)
4. PURITY AND IMPURITIES (name the measure with every number)
Purity measure 1 .................... ______ % by ______________
Purity measure 2 (orthogonal) ....... ______ % by ______________
Aggregate content ................... ______ % by ______________
confirmed by (different failure mode) ______________
Submicron / subvisible particles .... [ ] measured, method ____________
[ ] not measured (say so)
Process-related impurities .......... host-cell protein ______
host-cell DNA ______
leached ligand ______
Endotoxin ........................... ______ EU/mg by ______________
5. HIGHER-ORDER STRUCTURE AND STABILITY
Method(s) ........................... ______________________________
Result against reference preparation ______________________________
Thermal transition midpoint ......... ______ degrees C by ____________
6. ACTIVITY / POTENCY
Functional assay .................... ______________________________
What the readout measures ........... ______________________________
Result and acceptance range ......... ______________________________
Binding affinity (if reported) ...... ______ (NOT a substitute for potency)
7. HANDLING HISTORY (most often omitted; most often the cause of a failed replication)
Storage buffer, full composition .... ______________________________
pH ______ Concentration ______ mg/mL
Storage temperature ................. ______ Single-use aliquots? [ ] yes [ ] no
Freeze-thaw cycles before use ....... ______
Filtered before use? ................ [ ] yes, ______ micrometres [ ] no
Agitation / transport exposure ...... ______________________________
8. IF THE MATERIAL IS AN ASSEMBLY (lipid nanoparticle, liposome, micelle, particle)
Full composition with molar ratios .. ______________________________
Hydrodynamic size ______ nm PDI ______ Method ______________
Zeta potential ______ mV in ______________
Encapsulation efficiency ______ % by ______________
Morphology by ....................... ______________________________
Dispersion state in the biological medium actually used: ______________
9. WHAT NOT TO CLAIM
[ ] No immunogenicity prediction from an aggregate level
[ ] No potency inference from binding affinity alone
[ ] No in vivo prediction from in vitro release of an encapsulated payload Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing and regulatory writing teams prepare methods and quality sections for biologics from the analytical package rather than from the draft, covering the construct, production system, orthogonal purity and aggregation measures, higher-order structure, functional potency and the full handling history, each with its method named. The team also verifies that the claims made correspond to what the assays can support, which is where biologics manuscripts most frequently overstate their findings.